BRTX
BioRestorative Therapies, Inc.
NASDAQ · Healthcare · Biotechnology · US
$2.69
+1.32%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$2.69
From 52W high−4.02%
Volume16906.00
Market cap$3.72M
P/E (TTM)—
P/S (TTM)10.4x
Div yield—
Key dataSep 18, 2026
Open
$2.69
From 52W high
−4.02%
Volume
16906.00
Market cap
$3.72M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.0x
P/E (TTM)
—
RSI (14)
86.5
MomentumView details →
1D Return
+1.32%
YTD Return
+140.68%
SummaryUpdated Mar 1, 2026
BioRestorative Therapies, Inc. (OTCQB:BRTX) is a life sciences company founded in 1997 and based in Melville, New York, that focuses on developing regenerative medicine products using adult stem cell therapies. Originally incorporated as Stem Cell Assurance, Inc., the company changed its name to BioRestorative Therapies in August 2011 and went public in December 2012. The company operates two primary therapeutic programs: a disc/spine treatment program called brtxDisc and a metabolic disorders program called ThermoStem, both utilizing different types of stem cell technologies to address unmet medical needs.
Similar companies
Latest newsMore news →
Mr. Silva resigned as Vice President of Research and Development of BioRestorative Therapies, Inc., effective September 4, 2026.9d agoBioRestorative Therapies, Inc. dismissed CBIZ CPAs P.C. as its independent auditor and engaged Bush & Associates CPA, effective August 28, 2026.10d agoKatharyn Field resigned as Interim Chief Executive Officer, Chief Financial Officer, Treasurer, Secretary and Board member of BioRestorative Therapies, effective late August 2026, with successors appointed.18d ago